Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

NCT02265549 | Completed DMC

• 1 other identifier: Radiomics SRT 09-2014
• Study Type: observational
• Target: 155
• Locations: 1 country
• Sites: 1

Brief Summary

Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.

Conditions

Metastases, Neoplasm

Keywords

Metastases,; Neoplasm; Cerebral

Outcome Measures

Primary Outcomes (2)

• Sensitive value of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics

  Sensitivity of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.

  1 year

• Sensitive value of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics

  Sensitivity of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.

  1 year

Secondary Outcomes (3)

• Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

  1 year

• Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

  1 year

• Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

  1 year

Other Outcomes (2)

• Area under the curve of published prognostic scores

  1 year

• Mismatch rate of published prognostic scores

  1 year

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with 1 upto 4 brain metastases treated with SRT

You may qualify if:

• Cerebral metastasized patients

Sponsors & Collaborators

• Maastricht Radiation Oncology: lead

Study Sites (1)

Maastro Clinic

Maastricht, 6229 ET, Netherlands

Location

Related Publications (3)

• Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ, Lagerwaard FJ. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 2013 Mar;106(3):370-4. doi: 10.1016/j.radonc.2013.01.015. Epub 2013 Mar 20.

  PMID: 23522151 RESULT

• Rodrigues G, Zindler J, Warner A, Lagerwaard F. Recursive partitioning analysis for the prediction of stereotactic radiosurgery brain metastases lesion control. Oncologist. 2013;18(3):330-5. doi: 10.1634/theoncologist.2012-0316. Epub 2013 Feb 19.

  PMID: 23429647 RESULT

• Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014 Jun 3;5:4006. doi: 10.1038/ncomms5006.

  PMID: 24892406 RESULT

MeSH Terms

Conditions

Neoplasm Metastasis; Neoplasms

Condition Hierarchy (Ancestors)

Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2014
• First Posted: October 16, 2014
• Study Start: May 1, 2014
• Primary Completion: September 4, 2014
• Study Completion: September 4, 2014
• Last Updated: January 26, 2018

Record last verified: 2018-01

Locations

NL (1)